CereScan Welcomes Dr. Stuart Stein to Its Scientific and Medical Advisory Board

Share Article

CereScan Corp. adds noted Neurologist Stuart A. Stein, MD, MBA, MS to its Scientific and Medical Advisory Board, with plans for further additions in the near term.

The medical expertise on CereScan Corp’s Scientific and Medical Advisory Board has expanded with the addition of board certified Neurologist Stuart A. Stein, MD, MBA, MS. Dr. Stein will join current members, including (retired) Major General Gale Pollock, former Surgeon General of the U.S. Army, in advancing the company’s research, data and diagnostics development plans.

Dr. Stein brings 39 years of medical experience and his extensive medical research background to the board. He is an adult pediatric, and neonatal neurologist, a NIH fellowship- trained molecular biologist and Neurogeneticist, a translational informatician, a neurology department and regional chairman, a former scientific director of a large research institute, a specialist in animal models of human disease, and a stroke neurologist with a particular interest in acute care and prevention of stroke. Dr. Stein’s expertise includes the development of regional neurology departments and centers and in complex clinical and research programs and departments that are both national and international; all of these have been built on a combination of basic and clinical research, high level clinical care, and sound business principles. Most recently, he served as Director of Neurology and Neurology Program and the Stroke Center for the Banner Health East Valley Phoenix Region, as well as multiple prior academic appointments. He has broad and extensive clinical experience in complex neurological disorders, including epilepsy, stroke, neuroimmunological disorders, neurogenetics, mitochondrial and metabolic disorders, neurocritical care, and neurology/neurosurgery interfaces. He has particular expertise in non-invasive brain and neck blood vessel imaging. He has had long-term NIH research funding for 22 years as a principal investigator and he has been awarded and managed large numbers of contracts and grants. His research has also been funded by multiple Foundations. He has directed and built multidisciplinary research groups and has been a Visiting Professor on multiple occasions.

Dr. Stein currently serves as the CEO, President, and Managing Partner of several companies. One of the companies is developing acute and preventative diagnostic modalities and systems that are rapid and point of care, for TBI and stroke diagnosis, to promote early, safe, and state of the art care. Another company is a preventative Stroke Neurogenomics company.

Dr. Stein has his BS from the University of Michigan and earned his medical degree from Northwestern University’s Feinberg School of Medicine, a MBA in Health Sector and Health Policy Management from the University of Miami, and a MS in Biomedical and Translational Informatics (Clinical Genomics) from Arizona State University at Mayo Clinic in Scottsdale, AZ.

“CereScan provides a unique and important set of imaging modalities predicated on the use of PET and SPECT technologies and on quality data analysis and informatics that provides additional diagnostic precision and potential more definitive and appropriate treatment of TBI, and specific psychiatric and neurological disorders,” said Dr. Stuart Stein. “CereScan’s armamentarium of tools and already established applicability to TBI and specific brain disorder enhances and compliments standard brain imaging studies and neurological, neuropsychological and psychiatric evaluation for patient care. The need for identification of brain imaging abnormalities and their specific brain localizations are particularly important for military patients, post TBI in combat, and for TBI related to contact athletics in children and adults for rational prevention and other therapies to improve long term prognosis.”

“Stuart Stein is a long-time friend and advocate of CereScan,” said John Kelley, Chairman and CEO of CereScan Corp. “We are certainly fortunate to have his brilliant and unique insight at our disposal as we embark on an ambitious plan for development in key areas of our business.”

CereScan, is the nation’s leader in providing statistically measured brain diagnostics based on a new generation of imaging software, PET/CT (Positron Emission Tomography/Computed Tomography) and SPECT (Single Photon Emission Computed Tomography) neuroimaging technologies. Referring and treating medical experts can rely on CereScan to offer differentiated diagnoses on a wide array of brain-based disorders including:

  •     Traumatic Brain Injury
  •     Toxic Brain Injury
  •     Alzheimer’s Disease
  •     Mild Cognitive Impairment
  •     Other Dementias
  •     Parkinson’s Disease
  •     Obsessive Compulsive Disorder
  •     Bipolar Disorder
  •     ADD/ADHD
  •     Anxiety Disorder

About CereScan

CereScan combines state-of-the-art SPECT and PET/CT brain imaging technologies with a patient centered model of care to provide the highest level of neurodiagnostics anywhere. Using quantitative functional brain imaging, advanced imaging software, and an extensive library of clinical data, the CereScan medical team provides physicians with unmatched objective diagnostic information. CereScan helps patients and their physicians better understand the neurological basis of their conditions. In a variety of legal settings, CereScan provides objective evidence to attorneys and their clients regarding traumatic and toxic brain injuries. For researchers, CereScan provides independent pre- and post-treatment measures of organic changes in the brain along with measures of symptoms related to the brain disorder of interest. For more information, please call (866) 722-4806 or visit http://www.CereScan.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

John Kelley

Gail McClurg
@CereScan
Follow >
Visit website